Cipher Pharmaceuticals Inc. (CPHRF)

Overview

Cipher Pharmaceuticals Inc. is recognized as a specialty pharmaceutical company with its base of operations in Canada. It has carved its niche by focusing on the development and commercialization of innovative therapies for managing complex medical conditions. Since its founding in 2000, Cipher Pharmaceuticals has committed to improving patient quality of life through its diverse portfolio of therapies, targeting a variety of conditions ranging from dermatological issues to pain management. With its headquarters situated in Mississauga, Canada, the company has demonstrated a strong footprint in the pharmaceutical landscape through both its proprietary products and licensed medications. Cipher Pharmaceuticals Inc. plays a pivotal role in delivering advanced medical solutions, having built a solid pipeline of products in different stages of clinical trials, alongside successfully commercialized medicines.

Products and Services

• Epuris (isotretinoin)

A potent oral retinoid designed primarily for the treatment of severe forms of acne, including nodular, inflammatory, and recalcitrant types, offering a beacon of hope for those suffering from these debilitating dermatological conditions.

• Actikerall (topical solution)

This solution is aimed at treating actinic keratosis, specifically the slightly palpable and moderately thick varieties found on the face, forehead, and balding scalp, by offering a targeted approach to manage this pre-cancerous skin condition.

• Ozanex (for impetigo)

A topical treatment formulated for combatting impetigo, Ozanex represents an effective option for managing this highly contagious skin infection, common among children and adults alike.

• Vaniqa (topical cream)

Designed to slow the growth of unwanted facial hair in women, Vaniqa offers a dermatologically approved solution to manage hirsutism, thereby aiding in the improvement of patient self-esteem and quality of life.

• Durela (opioid analgesic)

Targeting the management of moderate to moderately severe pain in adults, Durela embodies the commitment to providing relief for patients experiencing chronic pain, through its controlled-release formulation.

• Brinavess

As a reversible GP IIb/IIIa inhibitor, Brinavess serves a critical role in the rapid conversion of onset atrial fibrillation to sinus rhythm in adults, showcasing Cipher's foray into acute coronary syndrome management.

• Aggrastat

This medication further underscores Cipher's involvement in the realm of acute coronary syndromes by providing a reversible GP IIb/IIIa inhibitor optimized for patients exhibiting acute coronary syndrome symptoms.

• Absorica

An oral retinoid similar to Epuris, Absorica is indicated for severe nodular and/or inflammatory acne, offering an advanced formulation for those battling with recalcitrant acne conditions.

• Lipofen

Targeting cholesterol management, Lipofen is used as an adjunctive therapy to diet for reducing LDL-C, total-C, triglycerides, Apo B, and to increase HDL-C, focusing on the comprehensive lipid profile improvement in adults.

• Conzip

Conzip, an opioid agonist, emphasizes Cipher's dedication to pain management through its indication for the management of moderate to moderately severe chronic pain in adults, contributing to the broader spectrum of pain management solutions.

• Pipeline Products

Cipher Pharmaceuticals Inc. is also investing in the future of healthcare with its pipeline products, including MOB-015 for onychomycosis, CF-101 (Piclidenoson) for severe plaque psoriasis, and rheumatoid arthritis, and DTR-001, a tattoo removal cream currently in pre-clinical stage, underscoring its ongoing commitment to innovative healthcare solutions.